Duopharma Biotech Bhd’s net profit for the second quarter ended June 30, rose 6% to RM14.73 million from RM13.92 million a year ago, thanks to local sales, but revenue fell by 1.5% to RM143.33 million versus RM145.47 million last year.
“Although 2020 is proving to be more challenging than previous years, we continue to remain cautiously optimistic of our FY2020 performance,“ he said in a statement. “Concurrently, we are preparing for the technology transfer process to Duopharma Biotech of a second product during August 2020.”
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む: